AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ocugen, Inc. Director's Dealing 2018

Apr 18, 2018

32915_dirs_2018-04-18_8b125c51-0af3-400f-abae-711d2a4767b7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2018-04-16

Reporting Person: Washer Susan B. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-16	Employee Stock Option (Right to Buy)	$2.84	A	25000	Acquired	2028-04-15	Common Stock (25000)	Direct

Footnotes

F1: Exercisable with respect to 8.33% of the shares in equal quarterly installments over 36 months of continuous service following the vesting commencement date.